Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

In patients with systemic lupus erythematosus (SLE), immature B cells that recognize self antigens fail to undergo apoptosis or suppression before maturation; one consequence is that untreated ...

B cells have important pathogenic roles in systemic lupus erythematosus (SLE): they produce autoantibodies, secrete inflammatory cytokines and might promote expansion of autoreactive T cells via ...

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Primary outcome measures were evaluation of frequency and rate of adverse events at 12 and 24 weeks, as well as baseline change in B cell and B-cell ... measures: SS, SLE flare Index (SFI ...

Systemic lupus erythematosus (SLE, lupus) is characterized by immune cell dysregulation including abnormalities in B lymphocytes, the antibody producing cell lineage of the immune system. In fact, ...

It is currently being studied for both cutaneous and systemic lupus erythematosus (SLE). Obinutuzumab (Gazyva®) is a treatment that works by blocking the activation of B cells, which contribute to ...

Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...

ADI-001 is an allogeneic gamma delta CAR T-cell therapy that targets the B-cell antigen CD20. The Food and Drug Administration (FDA) has granted Fast Track designation to ADI-001 for the treatment ...